CyFlow™ CD8a Low Endotoxin

CyFlow™ CD8a Low Endotoxin
Target Species: Mouse
Antigen: CD8a
Field of Interest: Immunophenotyping, MHC
Clone: 53-6.7
Regulatory Status: RUO
Alternative Name: Leu2, T8
Application: Flow cytometry, Functional assays, Immunocytochemistry, Immunohistochemistry, Immunoprecipitation
Format/Fluorochrome: Low Endotoxin
Species of Origin: Rat
Clonality: monoclonal
Isotype: IgG2a
Product number: AN289615

For Research Use Only

$130.00 USD*

Price excludes any applicable taxes plus shipping costs

Concentration 1 mg/mL Quantity 0.1 mg Volume 0.1 mL Immunogen Mouse spleen cells... more
CyFlow™ CD8a Low Endotoxin
Concentration1 mg/mL
Quantity0.1 mg
Volume0.1 mL
ImmunogenMouse spleen cells
Background InformationCD8a (CD8 α) subunit of CD8 T cell coreceptor is expressed in CD8 α/β heterodimers on majority of MHC I-restricted conventional T cells and thymocytes and in CD8 α/α homodimers on subsets of memory T cells, intraepithelial lymphocytes, NK cells, macrophages and dendritic cells. Regulation of CD8 β level on T cell surface seems to be an important mechanism to control their effector function. Assembly of CD8 α/β but not α/α dimers is connected with formation or localization to the lipid rafts. Recruiting triggered TCR complexes to these membrane microdomains as well as affinity of TCR to MHC I is modulated by CD8, thereby affecting the functional diversity of the TCR signaling.
Storage BufferThe reagent is provided in azide-free phosphate buffered saline (PBS) solution, pH ≈7.4; 0.2 µm filter sterilized. Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Ledbetter JA, Herzenberg LA: Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol·Rev. 1979; 47:63‑90. <·PMID:·398327·> | Ledbetter JA, Rouse RV, Micklem HS, Herzenberg LA: T cell subsets defined by expression of Lyt‑1,2,3 and Thy‑1 antigens: Two‑parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views. J·Exp·Med. 1980·Aug·1; 152(2):280‑95. <·PMID:·6156984·> | Takahashi K, Nakata M, Tanaka T, Adachi H, Nakauchi H, Yagita H, Okumura K: CD4 and CD8 regulate interleukin 2 responses of T cells. Proc·Natl·Acad·Sci·USA. 1992·Jun·15; 89(12):5557‑61. <·PMID:·1608966·> | Grabbe S, Varga G, Beissert S, Steinert M, Pendl G, Seeliger S, Bloch W, Peters T, Schwarz T, Sunderkötter C, Scharffetter-Kochanek K: Beta2 integrins are required for skin homing of primed T cells but not for priming naive T cells. J·Clin·Invest. 2002·Jan; 109(2):183‑92. <·PMID:·11805130·> | Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T, Sakaguchi S: Distinct contribution of IL‑6, TNF‑alpha, IL‑1, and IL‑10 to T cell‑mediated spontaneous autoimmune arthritis in mice. J·Clin·Invest. 2004·Aug; 114(4):582‑8. <·PMID:·15314695·> | Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY: alpha‑Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J·Immunol. 2005·Sep·1; 175(5):3309‑17. <·PMID:·16116223·> | Bouwer HG, Alberti-Segui C, Montfort MJ, Berkowitz ND, Higgins DE: Directed antigen delivery as a vaccine strategy for an intracellular bacterialpathogen. Proc·Natl·Acad·Sci·USA. 2006·Mar·28; 103(13):5102‑7. <·PMID:·16549792·> | Kamimura D, Sawa Y, Sato M, Agung E, Hirano T, Murakami M: IL‑2 in vivo activities and antitumor efficacy enhanced by an anti‑IL‑2 mAb. J·Immunol. 2006·Jul·1; 177(1):306‑14. <·PMID:·16785526·> | Mochimaru H, Usui T, Yaguchi T, Nagahama Y, Hasegawa G, Usui Y, Shimmura S, Tsubota K, Amano S, Kawakami Y, Ishida S: Suppression of alkali burn‑induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2. Invest·Ophthalmol·Vis·Sci. 2008·May; 49(5):2172‑7. <·PMID:·18263815·>

Article successfully added.